tradingkey.logo

Monte Rosa Therapeutics Announces First Subjects Dosed In Phase 1 Study Of Mrt-8102, A Nek7-Directed Molecular Glue Degrader For The Treatment Of Multiple Inflammatory Diseases

ReutersJul 21, 2025 11:01 AM

- Monte Rosa Therapeutics Inc GLUE.O:

  • MONTE ROSA THERAPEUTICS ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 STUDY OF MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES

  • MONTE ROSA THERAPEUTICS INC - INITIAL RESULTS FROM PHASE 1 STUDY EXPECTED IN H1 2026

  • MONTE ROSA THERAPEUTICS INC: MRT-8102 PHASE 1 STUDY INITIAL RESULTS ANTICIPATED IN H1 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI